Dr. Kolberg on the Cardiac Safety of ABP 980 in HER2-Positive Breast Cancer

Hans-Christian Kolberg, MD, head, Department of Obstetrics and Gynecology, Breast Cancer Center, and Gynecologic Cancer Center at Marienhospital Bottrop, Klinik für Gynäkologie und Geburtshilfe, Bottrop, Germany, discusses the safety profile of ABP 980 (Kanjinti; trastuzumab-anns) in early-stage HER2-positive breast cancer.

The phase III LILAC study is the only biosimilar registration study that allowed patients to switch from the biosimilar arm to the biologic arm. After patients underwent surgery, those assigned to the trastuzumab arm were re-randomized to receive either trastuzumab or ABP 980. This is important because many providers, in order to meet mandated quotas, will have to switch their patients from trastuzumab to ABP 980. This study showed that it is safe and feasible to do so, says Kolberg.

At the 2019 ASCO Annual Meeting, Kolberg presented data regarding the cardiac safety of ABP 980. Investigators showed that the incidence of cardiac events were the same between arms. Neither arm showed a higher rate of cardiac events despite the crossover, further proving that the approach is safe.